Top Ten most popular articles on Pharmafile.com this week!
pharmafile | May 3, 2019 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Eli Lilly, Gilead, autism, dementia, opioids, pharma
This week was marked by the failure of two Phase 3 trials after both Eli Lilly and Gilead suffered from poor results in late stage studies. Lilly’s failure was so such that they decided to withdraw Latruvo from the market.
Meanwhile research fared well after scientists outlined a new form of dementia. The discovery could help to develop new treatments for the disease. Similarly two separate trials showed the effectiveness of two different therapies based on the hormone vasopressin in improving social function in people with autism.
The findings were matched in significance by the discovery that diabetes drug exenatide might help people quit smoking. Check out the ten most popular stories of this week!
10. Opioids to be labelled with addiction warning in UK
All opioid medicines sold in the UK will be labelled with a warning as to the potential for addiction, Health Secretary Matt Hancock has announced.
9. Gilead’s selonsertib crashes at Phase 3 in NASH
Gilead has broken the news that its apoptosis signal-regulating kinase 1 (ASK1) inhibitor selonsertib failed to meet its primary endpoint at Phase 3 in the treatment of bridging fibrosis (F3) due to nonalcoholic steatohepatitis (NASH).
8. Two thirds of MPs believe NHS should spend less on medicines
Nearly two thirds (64%) of MPs believe the NHS should direct more resources towards prevention, over funding for new treatments, according to a poll of 100 parliamentarians.
7. Gilead subsidiary Kite Pharma to open CAR-T manufacturing facility in Maryland
Gilead Sciences subsidiary Kite Pharma has announced plans to open a new CAR-T manufacturing facility in Frederick County, Maryland (US).
6. India hits back at claims they are leading source of counterfeit drugs
India has rejected claims that they, along with China, are the chief source of counterfeit medicines around the world.
5. Hormone-based therapies show promise in children and adults with autism
A hormone-based therapy might improve social function in people with autism, according to the results of two separate clinical trials.
4. Diabetes drug may help people quit smoking
A diabetes drug may help people quit smoking, according to researchers at the University of Texas Health Science Center at Houston (UTHealth).
3. Scientists identify new form of dementia
A team of scientists from Britain and the United States have described a new form of dementia, according to a study published in the journal Brain.
2. The price of access: Can the NHS afford Orkambi?
The impasse over access to Vertex’s Orkambi for cystic fibrosis patients in England and Wales has revealed the cracks in the NHS’ regulatory system. Matt Fellows explores where the core issues lie in the debate, and what can be done to prevent future breakdowns in communication for the good of patients.
1. Eli Lilly to withdraw Lartruvo from market in soft tissue sarcoma following Phase 3 failure
Eli Lilly has revealed it is to withdraw its platelet-derived growth factor receptor alpha (PDGFR-α) blocking antibody Lartruvo (olaratumab) from the market as a treatment for advanced soft tissue sarcoma (STS) due to the drug’s failure to adequately address the condition in Phase 3 trials.
Related Content
Eli Lilly acquires new manufacturing facility from Nexus Pharmaceuticals
Eli Lilly and Nexus Pharmaceuticals have announced that they have entered into a definitive agreement …
Eli Lilly’s tirzepatide demonstrates efficacy in reducing sleep apnoea severity
Eli Lilly has announced positive topline results from its SURMOUNT-OSA phase 3 trials which demonstrated …
Zuellig Pharma acquires Cialis and Alimta from Eli Lilly in certain ASEAN markets
Zuellig Pharma has announced that it has completed the acquisition of two brands Cialis (Tadalafil) …
